Sargramostim Solution for Injection and Tisagenlecleucel Intravenous
Determining the interaction of Sargramostim Solution for Injection and Tisagenlecleucel Intravenous and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using sargramostim during or too soon after tisagenlecleucel infusion may alter the effects of both treatments. Medications like sargramostim should generally not be given for at least 3 weeks after tisagenlecleucel treatment or until resolution of cytokine release syndrome (CRS), which is a potentially life-threatening condition that may occur following treatment with tisagenlecleucel and often requires hospitalization. Signs and symptoms of CRS include dizziness; lightheadedness; low blood pressure; high fever; difficulty breathing; chills or shaking chills; severe nausea, vomiting, and diarrhea; and severe muscle and joint pain. Heart, liver, or kidney function may also be affected in some patients with CRS. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:ADJUST DOSING INTERVAL: Concurrent administration of tisagenlecleucel and hematopoietic growth factors may interfere with the pharmacologic effects of both, since the former targets B-cell lymphoblasts and the latter stimulate myeloid cell proliferation.
MANAGEMENT: Hematopoietic growth factors, particularly granulocyte-macrophage colony-stimulating factor (GM-CSF), are not recommended during the first 3 weeks following tisagenlecleucel administration or until cytokine release syndrome (CRS) has resolved.
- "Product Information. Kymriah (tisagenlecleucel)." Novartis Pharmaceuticals, East Hanover, NJ.
Generic Name: sargramostim
Brand name: Leukine
Synonyms: Sargramostim
Generic Name: tisagenlecleucel
Brand name: Kymriah
Synonyms: Tisagenlecleucel
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Sargramostim Solution for Injection-Titralac
- Sargramostim Solution for Injection-Tivicay
- Sargramostim Solution for Injection-Tivicay (Dolutegravir 10 mg)
- Sargramostim Solution for Injection-Tivicay (Dolutegravir 25 mg and 50 mg)
- Sargramostim Solution for Injection-Tivorbex
- Sargramostim Solution for Injection-Tizanidine
- Tisagenlecleucel Intravenous-Sarilumab
- Tisagenlecleucel Intravenous-Sarilumab Prefilled Pens
- Tisagenlecleucel Intravenous-Sarilumab Prefilled Syringes
- Tisagenlecleucel Intravenous-Sarilumab Subcutaneous
- Tisagenlecleucel Intravenous-Sarna Hc Topical application
- Tisagenlecleucel Intravenous-Sarnol-HC